Impressive Results from ibrutinib Study Conducted at John Theurer Cancer Center Lead to FDA Approval of Imbruvica as a Single Agent for Patients with

28-11-2013 Business Wire HealthComments (0)

ibrutinibOncologyPharmaceutical

Impressive Results from ibrutinib Study Conducted at John Theurer Cancer Center Lead to FDA Approval of Imbruvica as a Single Agent for Patients with Mantle Cell Lymphoma

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top